| Bioactivity | Felvizumab (SB 209763) is a humanized IgG1κ monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV[1][2]. |
| Target | EC50: 0.49 μg/mL (RSV Type A in microneutralization assay), 0.95 μg/mL (RSV Type A in fusion inhibition assay) |
| Invitro | Felvizumab (RSHZ19) (2 h or 4 h) 抑制 RSV A 型，微量中和试验中 EC50 为 0.49 ± 0.37 μg/mL，融合抑制试验中 EC50 为 0.95 ± 0.13 μg/mL[2]。 |
| In Vivo | Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) 在 RSV 感染大鼠模型中对 A 和 B 亚型 RSV 有效[2]。 Animal Model: |
| Name | Felvizumab |
| CAS | 167747-20-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fenton C, et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs. 2004;6(3):177-97. [2]. Johnson S, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis. 1999 Jul;180(1):35-40. |